Slice of Healthcare

IN THE SPOTLIGHT

CQ Medical Acquires Bionix Radiation Therapy Unit

CQ Medical Acquires Bionix Radiation Therapy Unit

Slice of Healthcare Team

12/02/2025

BioSked Launches AI-Driven Radiology Scheduling

BioSked Launches AI-Driven Radiology Scheduling

Slice of Healthcare Team

12/02/2025

LATEST ARTICLES

Medicare Approves Vivistim Payment Change for 2026

Slice of Healthcare Team

11/26/2025

Nucs AI Launches TrackPSMA for Prostate Cancer Care

Slice of Healthcare Team

11/26/2025

AI Uncovers Imaging Biomarker for Chronic Stress

Slice of Healthcare Team

11/25/2025

Mazdutide 9 mg Application Accepted by NMPA

Slice of Healthcare Team

11/25/2025

Podcasts

Slice of Healthcare Podcast

BioBreakthroughs

KestyMD Esthetics

See more podcasts

LATEST PODCAST EPISODES

Inside the ‘Big Unlock’: How UpToDate Is Reinventing Clinical Decisions

Slice of Healthcare Team

11/19/2025

#525 - Kenneth Young, CEO at Medecision and Mike Green, Managing Partner at Excell Healthcare Advisors

Slice of Healthcare Team

11/12/2025

Episode 56 - DTA Conference Recap, CMS Medical-Dental Integration, HS One Partners with AWS

Slice of Healthcare Team

11/12/2025

Episode 55 - Conversation with Mitch Olan | DSO Landscape Insights

Slice of Healthcare Team

11/05/2025

Awards

●Honorees Announced

50 Under 50 - 2025

The Slice of Healthcare 50 Under 50 list for 2025 celebrates 50 of the most dynamic and influential leaders in the healthcare industry under the age of 50. This annual recognition highlights individuals who are driving innovation, improving patient outcomes, and shaping the future of healthcare across various sectors, including digital health, biotechnology, and clinical services.

●Applications closed

CDI Leaders to Watch - 2025

The CDI Leaders to Watch award recognizes the most impactful and forward-thinking professionals in Clinical Documentation Integrity.

See more awards

Companies

Wally Health

Wally Health

At Wally, we are building the future of dental care. We offer one membership for $249 per year, that provides unlimited dental cleanings and check-ups – no insurance needed.

Baylor Genetics

Baylor Genetics

Baylor Genetics is a leading diagnostic genomics partner offering a full spectrum of clinically relevant genetic testing, including Whole Genome Sequencing, Whole Exome Sequencing, and focused panels. Baylor Genetics combines rapid and comprehensive precision diagnostics options with the support of genetic counselors to help clinicians avoid a lengthy diagnostic odyssey for their patients, guide medical management, and ensure no patient with a genetic disorder gets left behind. Baylor Genetics’ testing menu covers family planning, pregnancy, neonatal and pediatric testing, oncology, and many other specialized testing options. Located in Houston’s Texas Medical Center, Baylor Genetics serves clients in 50 states.

BioSked

BioSked

Bionix

Bionix

See more companies

Vaults

Boston

Boston

The Boston Vault features top podcasts, news, and awards shaping the future of healthcare from the Boston area.

Biotech

Biotech

The Biotech Vault features top podcasts, news, and awards shaping the future of biotechnology and innovation.

Oral Health

Oral Health

The Oral Health Vault features top podcasts, news, and awards shaping the future of dental care and innovation.

Artificial Intelligence

Artificial Intelligence

The AI Vault features top podcasts, insights, and news shaping the future of AI in healthcare.

See more vaults

Slice of Healthcare
Mavrix Bio Doses First Patient In Ascend As Trial

Slice of Healthcare

“Slices” on the people and organizations in healthcare via news, thoughts, podcasts, spotlights and more!

CONTENT

Home
Podcasts

EXPLORE

Awards
Vaults

DIRECTORY

Companies
Events
Committees

CONTRIBUTE

© 2025 Slice of Media, Inc.

MavriX Bio Doses First Patient in ASCEND-AS Trial

MavriX Bio Doses First Patient in ASCEND-AS Trial

MavriX Bio Doses First Patient in ASCEND-AS Trial

Slice of Healthcare Team

11/10/2025

Key highlights

First patient dosed in ASCEND-AS trial
MVX-220 targets UBE3A gene restoration
FDA grants Orphan Drug Designation for MVX-220
Collaboration with FAST and AS2Bio
Potential breakthrough for Angelman syndrome treatment

Source: PR Newswire

Notable Quotes

Expert Insights

Share Your Expert Insights

Have relevant experience or professional perspective? Add your thoughtful insights to this article.

“ Dosing our first participant in the ASCEND-AS trial is a critical step in evaluating the potential of gene targeted therapies for AS. ”

Jennifer Panagoulias, COO at MavriX Bio

“ This trial represents a new era in Angelman syndrome research. ”

Dr. Elizabeth Berry-Kravis, MD, PhD at Rush University Medical Center

Why this matters

The ASCEND-AS trial is a groundbreaking step in the treatment of Angelman syndrome, potentially offering hope to thousands affected by this rare genetic disorder. This development is particularly significant for the healthcare sector.

Keep reading

CQ Medical Acquires Bionix Radiation Therapy Unit

CQ Medical Acquires Bionix Radiation Therapy Unit

Slice of Healthcare Team

12/02/2025

Inside the ‘Big Unlock’: How UpToDate Is Reinventing Clinical Decisions

Inside the ‘Big Unlock’: How UpToDate Is Reinventing Clinical Decisions

Slice of Healthcare Team

11/19/2025

BioSked Launches AI-Driven Radiology Scheduling

BioSked Launches AI-Driven Radiology Scheduling

Slice of Healthcare Team

12/02/2025

#525 - Kenneth Young, CEO at Medecision and Mike Green, Managing Partner at Excell Healthcare Advisors

#525 - Kenneth Young, CEO at Medecision and Mike Green, Managing Partner at Excell Healthcare Advisors

Slice of Healthcare Team

11/12/2025